AHR and cancer: Cancer cell-derived kynurenine activation of the AhR, driving a decrease in melatonin will increase tolerogenic Tregs, whilst the loss of melatonin optimization of DC function contributes to suppressed activation of CD8+ t cells in the tumor microenvironment.